Zilretta Labeling Updated to Include Information Pertaining to Repeat Administration
MPR,
The Food and Drug Administration has approved a supplemental New Drug Application (sNDA) to update the product labeling for…
The Food and Drug Administration has approved a supplemental New Drug Application (sNDA) to update the product labeling for…
TORONTO – The barren pharmacologic landscape in osteoarthritis today is reminiscent of rheumatoid arthritis 30 years ago: few…
Dr. Spitzer Co-director Joint Replacement Program Cedars-Sinai Orthopedic Center Los Angeles, CA Many patients receive repeat…
Company reported net ZILRETTA ® (triamcinolone acetonide extended-release injectable suspension) sales of $22.5 million for full…
Company reported net ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) sales of $22.5 million for full-y…
medwireNews : Findings from an open-label phase IIIb trial suggest that repeat administration of extended-release triamcinolone…
medwireNews: Findings from an open-label phase IIIb trial suggest that repeat administration of extended-release triamcinolone…
Data from - Curated by - Date added Flexion Therapeutics announced that the results from an open-label Phase IIIb clinical…
Results from Phase 3b clinical trial indicate that repeat administration of ZILRETTA for osteoarthritis (OA) knee pain was…
Results from Phase 3b clinical trial indicate that repeat administration of ZILRETTA for osteoarthritis (OA) knee pain was…